The S&P 500 is soaring to new records driven by Nvidia, while less-important companies fall and remain far below their highs. Read More...
Sarepta Jumps on Broad Approval for Muscular Dystrophy Drug
(Bloomberg) — Sarepta Therapeutics Inc.’s gene therapy received expanded US approval to include more children with a deadly muscle disease, expanding the market for a controversial treatment that still hasn’t proved its benefit in clinical trials.Most Read from BloombergCar Dealerships Across US Halt Services After CyberattackCDK Tells Car Dealers Their Systems Likely Offline Several DaysPutin’s Hybrid War Opens a Second Front on NATO’s Eastern BorderUnited Airlines Jet Turns Back After Engine
Bloomberg•
Add Comment